

## **HB 7107 – Controlled Substances (Similar SB 7082)**

This bill amends s. 893.03, F.S., adding s. 893.03(5)(d), F.S. to include the following: “a drug product in finished dosage formulation that has been approved by the United States Food and Drug Administration that contains cannabidiol (2-[1R-3-methyl-6R-(1-methylethenyl)-2-cyclohexen-1-yl]-5-pentyl-1,3-benzenediol) derived from cannabis and no more than 0.1 percent (w/w) residual tetrahydrocannabinols.” This bill also amends s. 893.02(3), F.S. stating that the definition of “cannabis” does not include a drug product described in s. 893.03(5)(d), F.S. This new language would impact Epidiolex, removing it from Schedule I substances and moving it to Schedule V substances. Other future products fitting this definition would also be impacted.

Per DOC, in FY 17-18, there were 226 commitments for marijuana/cannabis related offenses. Of these commitments, 113 involved sale/manufacture/delivery, 26 involved sales within 1,000 feet of a church or business, 45 involved possession over 20 grams, and 42 involved trafficking in cannabis between 25 and 2,000 pounds. It is not known how many offenses involved Epidiolex, but it is expected that such offenses would be low in volume.

**CONFERENCE ADOPTED ESTIMATE: Negative Insignificant**

**Requested by: Senate**